Can prolotherapy be used to treat knee pain?

Prolotherapy for Knee Pain

Prolotherapy is conditionally recommended against for knee osteoarthritis based on the highest quality guideline evidence, which shows only small effect sizes in a limited number of trials with substantial variability in protocols. 1

Guideline Recommendations

The 2019 American College of Rheumatology/Arthritis Foundation guideline provides the most definitive stance on prolotherapy for knee OA. The conditional recommendation against prolotherapy is based on:

• Limited number of trials with small participant numbers
• Small effect sizes when benefit was demonstrated
• Substantial variability in injection schedules, injection sites, and comparators between trials
• Insufficient evidence to support routine use 1

Notably, the 2022 AAOS guideline does not address prolotherapy at all in their comprehensive review of knee OA management, focusing instead on corticosteroid injections (with considerable supporting evidence) and platelet-rich plasma (with inconsistent results) 2. This omission from a major orthopedic guideline further underscores the lack of robust evidence for prolotherapy.

Clinical Context and Nuances

The conditional (rather than strong) recommendation against prolotherapy means it may be considered in specific clinical scenarios:

• When first-line treatments have failed (NSAIDs, weight loss, exercise, physical therapy)
• When corticosteroid injections provide inadequate or short-lived benefit (typically 3 months) 2
• In patients who refuse or cannot undergo surgery
• As part of shared decision-making when patients understand the limited evidence

Recent Research Findings

While recent studies (2023-2024) show some positive results for dextrose prolotherapy, these must be interpreted cautiously:

• Studies demonstrate pain reduction and functional improvement compared to saline 3, 4
• Combination intra-articular plus peri-articular injection may be more effective than single approaches 5
• Benefits appear at 1-3 month follow-up, but long-term efficacy remains unclear 6, 4

Critical limitations of this research:

• Small sample sizes (typically 50-60 patients)
• Short follow-up periods (maximum 6 months in most studies)
• Lack of standardization in dextrose concentration (5%, 15%, 25%)
• Variable injection protocols and anatomical targets
• No comparison to established treatments like corticosteroids in most trials

Practical Algorithm

If considering prolotherapy despite the conditional recommendation against:

1. Ensure failure of evidence-based treatments first:

   • Weight loss (if BMI >25)
   • Structured exercise program
   • Oral NSAIDs or acetaminophen
   • Intra-articular corticosteroid injection

2. Patient selection criteria:

   • Kellgren-Lawrence grade 2-3 OA (not severe grade 4)
   • Pain duration >3 months
   • No knee effusion present
   • Realistic expectations about limited evidence

3. If proceeding, use standardized protocol:

   • 5% dextrose for peri-articular injection
   • 25% dextrose for intra-articular injection
   • Combined intra-articular and peri-articular approach appears superior 5
   • 2-3 injections at 1-2 week intervals
   • Ultrasound guidance recommended

Common Pitfalls

• Do not use prolotherapy as first-line treatment - it lacks the evidence base of NSAIDs and corticosteroids
• Avoid in severe (grade 4) OA - research suggests worse outcomes in advanced disease, similar to platelet-rich plasma 2
• Do not present as "regenerative" cure - evidence shows symptomatic improvement only, not disease modification
• Recognize insurance typically does not cover - patients bear out-of-pocket costs for a treatment with limited evidence

Comparison to Other Injectables

For context, the evidence hierarchy for knee OA injectables:

1. Corticosteroids: 19 high-quality + 6 moderate-quality studies supporting use (duration ~3 months) 2
2. Prolotherapy: Limited trials, small effect sizes, conditional recommendation against 1
3. Hyaluronic acid: 17 high-quality + 11 moderate-quality studies showing inconsistent results, recommended against routine use 2
4. Platelet-rich plasma: Strongly recommended against due to lack of standardization and inconsistent evidence 1

The evidence supporting prolotherapy is weaker than corticosteroids but the recommendation is less restrictive than for PRP or stem cells, which are strongly recommended against.